NASDAQ:IDYA IDEAYA Biosciences Q2 2025 Earnings Report $37.59 +0.14 (+0.37%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$37.62 +0.03 (+0.08%) As of 09/11/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast IDEAYA Biosciences EPS ResultsActual EPS-$0.88Consensus EPS -$0.85Beat/MissMissed by -$0.03One Year Ago EPS-$0.68IDEAYA Biosciences Revenue ResultsActual Revenue$6.00 millionExpected Revenue$3.48 millionBeat/MissBeat by +$2.52 millionYoY Revenue GrowthNaNIDEAYA Biosciences Announcement DetailsQuarterQ2 2025Date8/5/2025TimeBefore Market OpensConference Call DateTuesday, August 5, 2025Conference Call Time6:00AM ETUpcoming EarningsIDEAYA Biosciences' Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, November 4, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) IDEAYA Biosciences Earnings HeadlinesCiti Reaffirms Their Buy Rating on IDEAYA Biosciences (IDYA)September 12 at 6:58 AM | theglobeandmail.comAnalysts Are Bullish on These Healthcare Stocks: IDEAYA Biosciences (IDYA), Medicus Pharma Ltd (MDCX)September 10 at 6:14 PM | theglobeandmail.comThis 38 Dollar Fund Holds Every Major AI Stock and Pays WeeklyThe biggest AI stocks like Nvidia, CrowdStrike, and Palantir now trade for hundreds of dollars a share. One fund owns them all for just $38 a share. This fund distributes income every Thursday, with a 34 percent annualized distribution rate, even though none of the underlying AI stocks pay dividends on their own. Tim Plaehn breaks down exactly how the fund works in a free video presentation.September 12 at 1:00 AM | Investors Alley (Ad)IDEAYA Biosciences, Inc. (IDYA) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeptember 10 at 6:00 PM | seekingalpha.comIDEAYA Biosciences, Inc.: IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as ...September 9 at 5:10 PM | finanznachrichten.deIdeaya Biosciences, Servier Dose First Patient in Phase-3 Primary Uveal Melanoma TrialSeptember 9 at 5:10 PM | finance.yahoo.comSee More IDEAYA Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like IDEAYA Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IDEAYA Biosciences and other key companies, straight to your email. Email Address About IDEAYA BiosciencesIDEAYA Biosciences (NASDAQ:IDYA) is a clinical-stage biotechnology company focused on developing precision medicines for cancer. The company uses insights from tumor genetics and synthetic lethality—the targeting of vulnerabilities created by specific genetic alterations—to identify therapies intended for molecularly defined patient populations. IDEAYA’s investigational pipeline includes darovasertib (IDE196), a protein kinase C inhibitor being studied in genetically defined cancers, including metastatic uveal melanoma associated with GNAQ or GNA11 mutations. The company is also developing IDE397, an inhibitor of methionine adenosyltransferase 2A (MAT2A) designed to target tumors with MTAP gene deletions. Its research and development activities include discovery programs, clinical trials, and collaborations with pharmaceutical and biotechnology partners. Founded in 2015, IDEAYA is headquartered in South San Francisco, California, and develops therapies for patients in international clinical and commercial markets through its research programs and industry collaborations. The company is led by Yuval Cohen, Ph.D., who serves as chief executive officer and has been associated with IDEAYA since its founding.View IDEAYA Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/07 - 09/11Kroger’s Textbook Entry for Buy-and-Hold InvestorsOracle’s AI Spending Is Still Huge, But the Payoff Is Starting to Show in EarningsAmgen Drops 10% on a Trial It Didn't Even RunOil Above $100 Is Creating a New Opportunity Beyond the Major ProducersAST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing WindowAmerican Eagle Goes on Sale: Is It Time to Buy? Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
